HRP20100208T1 - Postupak liječenja akutnog rinosinusitisa - Google Patents

Postupak liječenja akutnog rinosinusitisa Download PDF

Info

Publication number
HRP20100208T1
HRP20100208T1 HR20100208T HRP20100208T HRP20100208T1 HR P20100208 T1 HRP20100208 T1 HR P20100208T1 HR 20100208 T HR20100208 T HR 20100208T HR P20100208 T HRP20100208 T HR P20100208T HR P20100208 T1 HRP20100208 T1 HR P20100208T1
Authority
HR
Croatia
Prior art keywords
mometasone furoate
use according
amount
ranges
mometasone
Prior art date
Application number
HR20100208T
Other languages
English (en)
Inventor
Bloom Melvyn
Danzig Melvyn
Rohane Patricia
Staudinger Heribert
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34825945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100208(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of HRP20100208T1 publication Critical patent/HRP20100208T1/hr
Publication of HRP20100208T8 publication Critical patent/HRP20100208T8/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)

Abstract

Upotreba aerosoliziranih čestica mometazon-furoata u pripravi farmaceutskog pripravka za liječenje akutnog rinosinusitisa kod gornjih dišnih puteva kod pacijenata pogođenih navedenom bolešću, bez istodobne primjene antibiotika, naznačena time što navedeni pripravak se formulira za primjenu najmanje jednom dnevno na površine navedenih dišnih puteva kod navedenih pacijenata količine aerosoliziranih čestica mometazon-furoata djelotvorne u liječenju navedene bolesti. Patent sadrži još 11 patentnih zahtjeva.

Claims (12)

1. Upotreba aerosoliziranih čestica mometazon-furoata u pripravi farmaceutskog pripravka za liječenje akutnog rinosinusitisa kod gornjih dišnih puteva kod pacijenata pogođenih navedenom bolešću, bez istodobne primjene antibiotika, naznačena time što navedeni pripravak se formulira za primjenu najmanje jednom dnevno na površine navedenih dišnih puteva kod navedenih pacijenata količine aerosoliziranih čestica mometazon-furoata djelotvorne u liječenju navedene bolesti.
2. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što navedena količina mometazon-furoata se kreće u rasponu od otprilike 25 µg do otprilike 1600 µg aerosoliziranih čestica mometazon-furoata.
3. Upotreba u skladu s patentnim zahtjevom 2, naznačena time što navedena količina mometazon-furoata se kreće u rasponu od otprilike 25 µg do otprilike 800 µg.
4. Upotreba u skladu s patentnim zahtjevom 3, naznačena time što navedena količina mometazon-furoata se kreće u rasponu od otprilike 25 µg do otprilike 400 µg.
5. Upotreba u skladu s patentnim zahtjevom 4, naznačena time što navedena količina mometazon-furoata se kreće u rasponu od otprilike 25 µg do otprilike 200 µg.
6. Upotreba u skladu s patentnim zahtjevom 5, naznačena time što navedena količina mometazon-furoata se kreće u rasponu od otprilike 25 µg do otprilike 100 µg.
7. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što navedena količina mometazon-furoata je otprilike 100 µg, 200 µg ili 400 µg.
8. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što navedenu količinu mometazon-furoata se formulira za primjenu dvaput dnevno.
9. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što mometazon-furoat je mometazon-furoat monohidrat.
10. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što mometazon-furoat se formulira za primjenu u obliku vodene suspenzije.
11. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što mometazon-furoat se formulira za primjenu u obliku suhog praha.
12. Upotreba u skladu s patentnim zahtjevom 11, naznačena time što mometazon-furoat je bezvodni mometazon-furoat.
HR20100208T 2004-01-21 2010-04-13 Postupak liječenja akutnog rinosinusitisa HRP20100208T8 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53783004P 2004-01-21 2004-01-21
PCT/US2005/002105 WO2005072704A2 (en) 2004-01-21 2005-01-19 Method of treating acute rhinosinusitis

Publications (2)

Publication Number Publication Date
HRP20100208T1 true HRP20100208T1 (hr) 2010-05-31
HRP20100208T8 HRP20100208T8 (hr) 2010-06-30

Family

ID=34825945

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100208T HRP20100208T8 (hr) 2004-01-21 2010-04-13 Postupak liječenja akutnog rinosinusitisa

Country Status (16)

Country Link
US (2) US20050186144A1 (hr)
EP (2) EP1711164B1 (hr)
JP (2) JP4976139B2 (hr)
AT (1) ATE461693T1 (hr)
CA (1) CA2554064A1 (hr)
CY (1) CY1110620T1 (hr)
DE (1) DE602005020113D1 (hr)
DK (1) DK1711164T3 (hr)
ES (2) ES2426957T3 (hr)
HR (1) HRP20100208T8 (hr)
MX (1) MXPA06008240A (hr)
PL (1) PL1711164T3 (hr)
PT (1) PT1711164E (hr)
RS (1) RS51335B (hr)
SI (1) SI1711164T1 (hr)
WO (1) WO2005072704A2 (hr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE461693T1 (de) * 2004-01-21 2010-04-15 Schering Corp Verfahren zur behandlung von akuten rhinosinusitis
AU2007311607A1 (en) * 2006-10-19 2008-04-24 Cipla Limited Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate
TWI411121B (zh) * 2010-03-11 2013-10-01 Ind Tech Res Inst 光吸收層之製造方法及應用其之太陽能電池結構
EP2938339B1 (en) * 2012-12-27 2020-08-19 Massachusetts Eye & Ear Infirmary Treatment of rhinosinusitis with p-glycoprotein inhibitors
JP7085485B2 (ja) 2016-01-15 2022-06-16 マサチューセッツ アイ アンド イヤー インファーマリー 分泌型ｐ－糖タンパク質は、慢性鼻副鼻腔炎の非侵襲的バイオマーカーである
AU2021297174A1 (en) * 2020-06-21 2023-02-02 Massachusetts Eye And Ear Infirmary Combination verapamil and mometasone therapy for the treatment of chronic rhinosinusitis
JP2024049405A (ja) * 2021-02-22 2024-04-10 興和株式会社 新規吸入剤

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE8790T1 (de) 1981-02-02 1984-08-15 Schering Corporation Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
US4731447A (en) 1985-05-13 1988-03-15 Schering Corporation Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4873335A (en) 1986-03-12 1989-10-10 Schering Corporation 3-phenethyl-2-benzene-amides or aza-derivatives thereof
DE69233150T2 (de) 1991-06-10 2004-06-24 Schering Corp. Fluorchlorkohlenwasserstoffreie Aerosolformulierungen
ATE203900T1 (de) * 1991-06-10 2001-08-15 Schering Corp Fluorchlorkohlenwasserstofffreie aerosolformulierungen
US6127353A (en) * 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US6068832A (en) 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
US5837713A (en) * 1997-02-26 1998-11-17 Mayo Foundation For Medical Education And Research Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6187765B1 (en) 1997-10-09 2001-02-13 Schering Corporation Mometasone furoate suspensions for nebulization
US6297227B1 (en) * 1998-09-10 2001-10-02 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
SE9803770D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Dry powder pharmaceutical formulation
US6465581B1 (en) * 2001-01-24 2002-10-15 The Goodyear Tire & Rubber Company Silica reinforced rubber composition which contains stabilized unsymmetrical coupling agents and article of manufacture, including a tire, having at least one component comprised of such rubber composition
AR036358A1 (es) * 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
EP1542753B1 (en) * 2002-08-23 2007-02-07 Schering Corporation Pharmaceutical compositions
US20040081625A1 (en) * 2002-10-21 2004-04-29 Schering Corporation Nasal formulations for the treatment of allergies
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US20040235807A1 (en) * 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
WO2005041931A2 (en) * 2003-10-20 2005-05-12 Schering Corporation Pharmaceutical aerosol compositions
ATE461693T1 (de) * 2004-01-21 2010-04-15 Schering Corp Verfahren zur behandlung von akuten rhinosinusitis
EP2651494B1 (en) 2010-12-13 2017-02-15 Pacesetter, Inc. Delivery catheter
US9106249B1 (en) 2014-09-04 2015-08-11 Semtech Corporation Calibration of a time-interleaved analog-to-digital converter

Also Published As

Publication number Publication date
JP2007518817A (ja) 2007-07-12
PL1711164T3 (pl) 2010-09-30
CA2554064A1 (en) 2005-08-11
CY1110620T1 (el) 2015-04-29
RS51335B (en) 2011-02-28
JP4976139B2 (ja) 2012-07-18
DE602005020113D1 (de) 2010-05-06
MXPA06008240A (es) 2006-08-31
US20050186144A1 (en) 2005-08-25
ATE461693T1 (de) 2010-04-15
ES2340777T3 (es) 2010-06-09
EP2201936A1 (en) 2010-06-30
ES2426957T3 (es) 2013-10-28
DK1711164T3 (da) 2010-07-19
HRP20100208T8 (hr) 2010-06-30
PT1711164E (pt) 2010-06-28
US20090022671A1 (en) 2009-01-22
WO2005072704A3 (en) 2006-07-20
EP1711164B1 (en) 2010-03-24
JP2008110991A (ja) 2008-05-15
EP2201936B1 (en) 2013-06-19
SI1711164T1 (sl) 2010-06-30
WO2005072704A2 (en) 2005-08-11
EP1711164A2 (en) 2006-10-18

Similar Documents

Publication Publication Date Title
HRP20100208T1 (hr) Postupak liječenja akutnog rinosinusitisa
RU2015138796A (ru) Способы и составы для лечения респираторных заболеваний
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
BR112017010551A2 (pt) composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento.
FR2903107B1 (fr) Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
HK1156847A1 (en) Pharmaceutical formulations and methods for treating respiratory tract infections
ME02495B (me) Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BRPI0517891A (pt) composições compreendendo azelastina e métodos de uso das mesmas
NO20024708D0 (no) Behandling av respiratoriske sykdommer
JP2016513688A5 (hr)
PT2322525E (pt) Derivados de purina para utilização como agonistas do recetor de adenosina a2a
BR0309670A (pt) Compostos derivados dicetohidrazina e drogas contendo os compostos como o ingrediente ativo
UA87123C2 (uk) Водна суспензія циклесоніду для аерозольного розпилення
BRPI0409427A (pt) composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
NO20075111L (no) Farmasoytisk sammensetning
HRP20130007T1 (hr) Lijeäśenje kognitivnih poremeä†aja pomoä†u (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamida i njegovih farmaceutski prihvatljivih soli
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
WO2007057221A3 (en) Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases
DE602006017728D1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
JP2009544665A5 (hr)
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales